Quantum Genomics SA (ALQGC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quantum Genomics SA (ALQGC) has a cash flow conversion efficiency ratio of -4.706x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.64 Million ≈ $-8.93 Million USD) by net assets (€1.62 Million ≈ $1.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Quantum Genomics SA - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how Quantum Genomics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALQGC total debt and obligations for a breakdown of total debt and financial obligations.
Quantum Genomics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quantum Genomics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tarapur Transformers Limited
NSE:TARAPUR
|
1.083x |
|
DOREL INDS INC. A
F:DO4C
|
N/A |
|
Throgmorton Trust Plc
LSE:THRG
|
0.018x |
|
Alzinova AB
ST:ALZ
|
-0.039x |
|
E-Pango SA
PA:ALAGO
|
0.368x |
|
SIV Capital Ltd
AU:SIV
|
0.020x |
|
Astrotech Corp
NASDAQ:ASTC
|
-0.228x |
|
Co-Diagnostics, Inc. Common Stock
NASDAQ:CODX
|
-0.301x |
Annual Cash Flow Conversion Efficiency for Quantum Genomics SA (2012–2022)
The table below shows the annual cash flow conversion efficiency of Quantum Genomics SA from 2012 to 2022. For the full company profile with market capitalisation and key ratios, see how much is Quantum Genomics SA worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €3.61 Million ≈ $4.22 Million |
€-20.21 Million ≈ $-23.63 Million |
-5.603x | -218.28% |
| 2021-12-31 | €9.67 Million ≈ $11.30 Million |
€-17.02 Million ≈ $-19.89 Million |
-1.760x | -261.87% |
| 2020-12-31 | €24.65 Million ≈ $28.82 Million |
€-11.99 Million ≈ $-14.02 Million |
-0.486x | +56.12% |
| 2019-12-31 | €9.41 Million ≈ $11.00 Million |
€-10.43 Million ≈ $-12.19 Million |
-1.109x | -20.70% |
| 2018-12-31 | €11.87 Million ≈ $13.87 Million |
€-10.90 Million ≈ $-12.74 Million |
-0.919x | -2.15% |
| 2017-12-31 | €8.87 Million ≈ $10.37 Million |
€-7.98 Million ≈ $-9.33 Million |
-0.899x | -91.70% |
| 2016-12-31 | €11.79 Million ≈ $13.79 Million |
€-5.53 Million ≈ $-6.47 Million |
-0.469x | -19.75% |
| 2015-12-31 | €8.02 Million ≈ $9.38 Million |
€-3.14 Million ≈ $-3.67 Million |
-0.392x | -101.82% |
| 2014-12-31 | €-129.79K ≈ $-151.74K |
€-2.79 Million ≈ $-3.26 Million |
21.503x | +3447.81% |
| 2013-12-31 | €-1.63 Million ≈ $-1.90 Million |
€-987.00K ≈ $-1.15 Million |
0.606x | -9.37% |
| 2012-12-31 | €-918.08K ≈ $-1.07 Million |
€-614.00K ≈ $-717.83K |
0.669x | -- |
About Quantum Genomics SA
Quantum Genomics Société Anonyme is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.